CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-08 | SCHELLER RICHARD H Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2026-06-08 | HOMCY CHARLES J Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2026-06-01 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +14,853 | $10.42 | $155K | 14,853 |
| 2026-06-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −13,253 | $25.57 | $339K | 1,600 |
| 2026-06-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −1,600 | $26.36 | $42K | 0 |
| 2026-06-01 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,853 | 207,554 | ||
| 2026-06-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −6,090 | $26.20 | $160K | 344,897 |
| 2026-06-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −553 | $26.24 | $15K | 27,970 |
| 2026-05-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 32,308 |
| 2026-05-29 | Dandekar Atul CSBO | Sale 10b5-1 | −7,500 | $26.34 | $198K | 24,808 |
| 2026-05-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 36,643 | ||
| 2026-05-26 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −25,582 | $26.02 | $666K | 350,987 |
| 2026-05-22 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −4,504 | $26.00 | $117K | 376,569 |
| 2026-05-22 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −2,478 | $26.00 | $64K | 28,523 |
| 2026-05-15 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −1,822 | $26.00 | $47K | 381,073 |
| 2026-05-15 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −116 | $26.00 | $3K | 31,001 |
| 2026-05-14 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +15,000 | $10.42 | $156K | 15,000 |
| 2026-05-14 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −15,000 | $26.22 | $393K | 0 |
| 2026-05-14 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 222,407 | ||
| 2026-05-04 | Dandekar Atul CSBO | Option exercise | +8,320 | $10.42 | $87K | 18,823 |
Page 5 of 14 · 267 trades